Phreesia, Inc. (NYSE:PHR) will release earnings results for the third quarter after the closing bell on Monday, Dec. 8.Analysts expect the Wilmington, Delaware-based company to report quarterly earnings at 24 cents per share, up from 4 cents per share in the year-ago period. The consensus estimate for Phreesia's quarterly revenue is $120.03 million, compared to $106.8 million a year earlier, according to data from Benzinga Pro.On Sept. 4, Phreesia posted mixed results for the second quarter.Phreesia shares ...

Core Insights - Phreesia, Inc. is set to release its quarterly earnings on December 8, 2025, with analysts estimating an EPS of $0.24 and revenue of approximately $120 million [1][5] - The projected revenue of $120.13 million represents a 12.5% increase compared to the same quarter last year, indicating positive growth for the company [2][5] - The company's price-to-sales ratio is 2.72, and the enterprise value to sales ratio is 2.51, suggesting efficient capital use [3] - Phreesia has a low debt-to-equity ratio of 0.016, indicating minimal reliance on debt financing, and a current ratio of 2.12, reflecting a strong ability to cover short-term liabilities [3] Financial Metrics - Analysts estimate an EPS of $0.24 for the upcoming earnings report [5] - Projected quarterly revenue is $120.13 million, marking a 12.5% year-over-year increase [2][5] - The price-to-sales ratio of 2.72 indicates investors are willing to pay $2.72 for every dollar of sales [3] - The enterprise value to sales ratio of 2.51 suggests efficient capital utilization [3] Market Expectations - The upcoming earnings report and management discussion will be critical for determining future earnings expectations and stock price movements [4] - Investors are closely monitoring whether Phreesia will exceed earnings expectations, as a positive earnings report could lead to a stock price increase [4]

Core Insights - Wall Street analysts expect Phreesia (PHR) to report quarterly earnings of $0.00 per share, reflecting a year-over-year increase of 100% [1] - Revenue projections for Phreesia are set at $120.13 million, which represents a 12.5% increase from the same quarter last year [1] - There has been a 50% upward revision in the consensus EPS estimate over the last 30 days, indicating a significant reassessment by analysts [1] Revenue Estimates - Analysts estimate 'Revenue - Subscription and related services' to be $55.44 million, marking a 12.3% increase from the previous year [4] - 'Revenue - Network solutions' is projected to reach $37.46 million, indicating a 14.5% year-over-year change [4] - 'Revenue - Payment processing fees' is expected to be $27.25 million, reflecting a 10.3% increase compared to the prior year [5] Client and Volume Metrics - The average number of healthcare services clients is anticipated to be 4,530, up from 4,237 in the same quarter last year [5] - The consensus estimate for 'Patient payment volume' is $1.16 billion, compared to $1.08 billion from the previous year [5] - Analysts project a 'Payment facilitator volume percentage' of 81.3%, slightly up from 81.0% year-over-year [6] Stock Performance - Over the past month, Phreesia shares have declined by 10.6%, while the Zacks S&P 500 composite has seen a minor decrease of 0.1% [6] - Phreesia holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near future [6]

Core Viewpoint - The market anticipates that Phreesia (PHR) will report a year-over-year increase in earnings driven by higher revenues when it releases its quarterly results for the period ending October 2025 [1] Earnings Expectations - The earnings report is scheduled for December 8, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2] - The consensus estimate for Phreesia's quarterly earnings is projected at $0.00 per share, reflecting a year-over-year increase of +100%, with revenues expected to reach $120.13 million, a 12.5% increase from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised 50% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Phreesia is significantly higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1,100.00%, suggesting a bullish outlook from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Phreesia currently holds a Zacks Rank of 2, reinforcing the likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Phreesia was expected to incur a loss of $0.07 per share but instead reported earnings of $0.01, resulting in a surprise of +114.29% [13] - Over the past four quarters, Phreesia has consistently beaten consensus EPS estimates [14]

Company Overview - Phreesia, Inc. is a healthcare technology company focused on patient intake and engagement, aiming to enhance the patient experience and healthcare outcomes [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is 0.52%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 7.01%, indicating inefficiency in capital utilization [2][6] - The ROIC to WACC ratio for Phreesia is 0.074, further highlighting its challenges in generating returns above its cost of capital [2][6] Peer Comparison - Health Catalyst has a negative ROIC of -16.99% against a WACC of 6.57%, resulting in a ROIC to WACC ratio of -2.59, indicating worse performance than Phreesia [3] - Veracyte has a ROIC of 0.99% and a WACC of 13.50%, with a ROIC to WACC ratio of 0.073, suggesting it also struggles to generate sufficient returns, but is noted for having the highest growth potential among peers [4][6] - Accolade, Castle Biosciences, and Personalis all report negative ROICs of -31.79%, -4.28%, and -30.51% respectively, with their WACCs at 10.94%, 8.83%, and 11.72%, indicating significant challenges in generating returns above their cost of capital [5]

Core Insights - Conestoga Capital Advisors reported strong equity market performance in Q3 2025, with their Micro-Cap Composite returning 11.7% net-of-fees, while the Russell Microcap Growth Index returned 19.9% [1] Company Overview: Phreesia, Inc. (NYSE:PHR) - Phreesia, Inc. is a SaaS-based software and payment platform provider for the healthcare sector, headquartered in Wilmington, Delaware [2] - As of October 17, 2025, Phreesia's stock closed at $22.29 per share, with a market capitalization of $1.335 billion [2] Financial Performance - Phreesia reported a 15% year-over-year revenue growth in Q2 2026, totaling $117.3 million, with EBITDA margins expanding to 19% [3][4] - The company raised its full-year profitability outlook following better-than-expected Q2 results [3] Recent Developments - Phreesia announced the acquisition of AccessOne for $160 million, which is expected to add $35 million in revenue and $11 million in EBITDA [3] - The acquisition raised some investor concerns as it represents an expansion into a new area within their payments platform [3] Market Position - Phreesia was held by 28 hedge fund portfolios at the end of Q2 2025, indicating stable interest among institutional investors [4] - Despite its potential, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry less downside risk [4]

Core Insights - Phreesia has announced that Sara DiNardo, Vice President of Client Solutions, has been recognized in Becker's Hospital Review's 2025 list of Rising Stars [1] Company Highlights - The recognition of Sara DiNardo highlights Phreesia's commitment to leadership and innovation within the healthcare technology sector [1] - This accolade may enhance Phreesia's reputation and visibility in the industry, potentially attracting new clients and partnerships [1] Industry Context - The inclusion of leaders in healthcare technology in prestigious lists like Becker's Hospital Review's Rising Stars indicates a growing recognition of the importance of innovation and leadership in the healthcare sector [1] - Such recognitions can influence industry trends and encourage other companies to invest in talent development and innovative solutions [1]

Group 1 - The Relative Strength Index (RSI) is a technical analysis indicator that measures momentum on a scale of zero to 100, with a reading below 30 indicating that a stock is considered oversold [1] - Phreesia Inc (PHR) shares have an RSI reading of 29.7, indicating they have entered oversold territory after trading as low as $20.87 per share [2] - The current RSI reading of the S&P 500 ETF (SPY) is 61.3, suggesting a contrast in market sentiment between PHR and the broader market [2] Group 2 - PHR's 52-week low is $12.05 per share, while the 52-week high is $29.155, with the last trade recorded at $20.93 [4]

Company Overview - Phreesia, Inc. (NYSE: PHR) provides software solutions for healthcare providers to manage patient experiences, including scheduling, registration, payments, education, and clinical support [1] Market Context - The article references the author's experience in navigating various market conditions, including the dot-com bubble, financial crisis, and the coronavirus pandemic, highlighting the importance of understanding market extremes [1] Analyst Background - The author, Dr. Duru, has a strong academic background with a B.S. in Mechanical Engineering from Stanford University and a Ph.D. in Engineering-Economic Systems, along with extensive experience in operations research, management consulting, and data analytics [1] Investment Position - The author holds a beneficial long position in Phreesia shares, indicating confidence in the company's future performance [1]

Company Overview - Phreesia, Inc. (NYSE: PHR) provides software solutions for healthcare providers to manage patient experiences, including scheduling, registration, payments, education, and clinical support [1] Analyst Insights - Dr. Duru, a seasoned financial market analyst, emphasizes the importance of trading and investing around market extremes, offering unique perspectives through his blog "One-Twenty Two" [1] - The blog covers a variety of financial topics, including stocks, options, currencies, and Bitcoin, utilizing both technical and fundamental analysis for different trading strategies [1] Educational Background - Dr. Duru holds a B.S. in Mechanical Engineering and a Ph.D. in Engineering-Economic Systems from Stanford University, showcasing a strong academic foundation in both engineering and economic analysis [1] Professional Experience - Dr. Duru's professional background includes independent consulting in operations research, management consulting in product development, and expertise in price optimization software and business intelligence [1]